Stockscreener 앱 받기
8.88
2.09%
-0.19
전일 마감가:
$9.07
열려 있는:
$9.01
하루 거래량:
703.11K
Relative Volume:
0.78
시가총액:
$679.48M
수익:
$31,000
순이익/손실:
$-54.42M
주가수익비율:
-9.0816
EPS:
-0.9778
순현금흐름:
$-48.99M
1주 성능:
-8.07%
1개월 성능:
-20.14%
6개월 성능:
+72.43%
1년 성능:
+48.62%
1일 변동 폭
$8.79
$9.0999
1주일 범위
$9.03
$10.18
52주 변동 폭
$4.35
$14.00
Candel Therapeutics Inc Stock (CADL) Company Profile
명칭
Candel Therapeutics Inc
전화
617-916-5445
주소
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
8.88 | 679.48M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
508.15 | 128.80B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.82 | 95.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.63 | 82.33B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.39 | 53.54B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.90 | 42.30B | 5.76B | 514.49M | 1.10B | 4.4813 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-07-13 | 개시 | Stifel | Buy |
| 2026-04-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-28 | 개시 | Stephens | Overweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-30 | 재개 | H.C. Wainwright | Buy |
| 2025-02-20 | 개시 | Citigroup | Buy |
| 2025-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-02-07 | 개시 | BofA Securities | Buy |
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-08-23 | 개시 | Credit Suisse | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
| 2021-08-23 | 개시 | UBS | Buy |
모두보기
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
A director receives 2,189 options instead of quarterly cash pay at Candel Therapeutics (CADL). - Stock Titan
Candel Therapeutics to Present at the SITC 2026 Annual Meeting - GlobeNewswire Inc.
Form 4 Candel Therapeutics Inc For: 2 October By Investing.com - Investing.com Nigeria
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
CADL Slides As Form 144 Filing Flags Insider Selling Risk - timothysykes.com
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com Australia
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com South Africa
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com India
Candel Therapeutics (NASDAQ: CADL) CEO sells 280K shares under preset plan - Stock Titan
Candel Therapeutics (NASDAQ: CADL) investor plans $3.4M Rule 144 stock sale from equity awards - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com India
Candel (CADL) gives director options with 36-month vesting - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com Canada
Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 - marketscreener.com
Candel Therapeutics Adds Regulatory Veteran to Board Ahead of Q4 2026 BLA Submission - Minichart
Candel Therapeutics Adds Martine Zimmermann to Board Ahead of Planned BLA Filing - citybiz
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Canada
Candel Therapeutics appoints Martine Zimmermann to board - investing.com
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - The Manila Times
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com UK
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - Yahoo Finance
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Nigeria
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
CADL 8-K FilingsCandel Therapeutics, Inc. SEC 8-K - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Show Me The Money: CADL Delivers 190%+ Gain In Less Than Six Months As BLA Filing Nears - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com Canada
Candel Therapeutics stock hits 52-week high at $13.96 - investing.com
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com UK
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight - PR Newswire UK
Candel Therapeutics to Present at September Investor Conferences - The Manila Times
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares of Stock - MarketBeat
Candel Therapeutics (CADL) CTO sells 7,000 shares via 10b5-1 plan - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Hits New 1-Year HighHere's Why - MarketBeat
Candel Therapeutics CTO Seshu Tyagarajan Executes 7,000-Share Sale Under 10b5-1 Plan - Kalkine Media
Candel Therapeutics (NASDAQ: CADL) insider plans 7,000-share 10b5-1 sale - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Trading 6.4% Higher Following Analyst Upgrade - MarketBeat
Freedom Broker raises Candel Therapeutics stock price target on trial progress - Investing.com Canada
Candel Therapeutics Inc (CADL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Candel Therapeutics Inc 주식 (CADL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tak Paul Peter | Chief Executive Officer |
Sep 11 '26 |
Sale |
10.46 |
59,379 |
620,891 |
113,321 |
| Tak Paul Peter | Chief Executive Officer |
Sep 10 '26 |
Sale |
11.50 |
220,866 |
2,539,893 |
172,700 |
| PAUL PETER TAK | Director |
Sep 10 '26 |
Proposed Sale |
12.17 |
280,245 |
3,410,582 |
0 |
| Tyagarajan Seshu | Chief Technology Officer |
Aug 17 '26 |
Sale |
12.00 |
7,000 |
84,000 |
76,865 |
| SESHU TYAGARAJAN | Officer |
Aug 17 '26 |
Proposed Sale |
11.72 |
7,000 |
82,040 |
0 |
| Barone Francesca | Chief Scientific Officer |
Jun 29 '26 |
Sale |
10.06 |
23,447 |
235,769 |
77,362 |
| Tyagarajan Seshu | Chief Technology Officer |
Jun 29 '26 |
Sale |
10.02 |
7,000 |
70,151 |
83,865 |
| SESHU P TYAGARAJAN | Officer |
Jun 29 '26 |
Proposed Sale |
9.79 |
7,000 |
68,530 |
0 |
| FRANCESCA BARONE | Officer |
Jun 29 '26 |
Proposed Sale |
9.79 |
23,447 |
229,546 |
0 |
| Manning Paul B | Director |
Feb 23 '26 |
Buy |
5.45 |
550,458 |
2,999,996 |
2,763,527 |
2.53%
0.80%
자본화:
|
볼륨(24시간):